Future Directions in Bladder Cancer Treatment: The Experts Weigh In

Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs. Neal Shore, Andrea Apolo, and Arjun Balar for this online on-demand activity as they dive into the latest data in bladder cancer therapies.

This activity is presented by Creative Educational Concepts and Bladder Cancer Advocacy Network and supported by independent educational grants from AstraZeneca and Genentech.

To complete the other activities in this series please click here. 

Target Audience

Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists. 

Learning Objectives

  • Monitor and review ongoing advanced bladder cancer trials with real time discussion of evidence-based data about new therapies. 

You may also be interested in

2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management

It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths.
Focusing on the Role of the Advanced Bladder Cancer Care Team: Case Studies on Managing irAEs

Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them.
IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success

As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs.
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
12/01/2020
Course expires: 
12/01/2022
Rating: 
0

 

  Neal Shore, MD, FACS (Activity Chair)
  Director, CPI, Carolina Urologic Research Center
  Atlantic Urology Clinics
  Myrtle Beach, South Carolina

 

 Andrea B. Apolo
 Medical Oncologist 
 Bethesda, Maryland 
 

 

 Arjun V. Balar, MD
 Director, Genitourinary Medical Oncology Program
 NYU Langone Perlmutter Cancer Center
 New York, New York 
 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-xxx-L01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.

 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-022-H01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.